ObalonBalloon Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • ObalonBalloon's estimated annual revenue is currently $5.8M per year.(i)
  • ObalonBalloon's estimated revenue per employee is $251,000

Employee Data

  • ObalonBalloon has 23 Employees.(i)
  • ObalonBalloon grew their employee count by 0% last year.

ObalonBalloon's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$24.1M9619%N/AN/A
#2
$9.5M3812%N/AN/A
#3
$4M16-11%N/AN/A
#4
$7.8M31-3%N/AN/A
#5
$5M20-5%N/AN/A
#6
$49.9M199-8%N/AN/A
#7
$16.8M67-17%$63.2MN/A
#8
$9.3M37-7%N/AN/A
#9
$36.6M14622%N/AN/A
#10
$64.3M2053%$502MN/A
Add Company

What Is ObalonBalloon?

Obalon is an engineering-driven medical technology company with a singular focus on innovative, high-quality gastric balloon technology. Located in San Diego, California, the technical team at Obalon has a long history of working closely with leading clinicians to develop innovative medical products that revolutionize treatment of chronic disease.

keywords:N/A

N/A

Total Funding

23

Number of Employees

$5.8M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ObalonBalloon News

2022-04-17 - Intragastric Balloons Market Size And Forecast | Silimed, Apollo ...

Silimed, Apollo Endosurgery, Medsil, Districlass Medical, Obalon Therapeutics, Allurion Technologies, Lexel, Helioscopie Medical Implants,...

2022-04-13 - Worldwide Intragastric Balloons Industry to 2029 - Key Drivers ...

The intragastric balloons types are categorized into single balloons, ... Fengh Medical, Medsil, Obalon Therapeutics, Phagia Technologies,...

2022-03-30 - ReShape Lifesciences Inc. (RSLS) CEO Bart Bandy on Q4 2021 Results - Earnings Call Transcript

... and regulatory requirements, manufacturing viability and quality system control necessary for reintroducing the Obalon Balloon System.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4M230%N/A
#2
$4.3M230%N/A
#3
$7.5M230%N/A
#4
$2.3M230%N/A
#5
$2.3M235%N/A